A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities
Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy. Particularly, a single molecule targeting more than one checkpoi...
Guardado en:
Autores principales: | Xiaopei Cui, Huifeng Jia, Hong Xin, Lei Zhang, Shi Chen, Simin Xia, Xue Li, Wei Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Yifan Zhan, Xiangyang Zhu, Xuemei Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a3b267fa67544fc5a32b0e5de324c6a1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein
por: Chen H, et al.
Publicado: (2018) -
VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer
por: Chen J, et al.
Publicado: (2017) -
Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies
por: Christina L. Parker, et al.
Publicado: (2020) -
Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy
por: Pan H, et al.
Publicado: (2018) -
Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
por: Madhu S. Pandey, et al.
Publicado: (2021)